Fungating Metastatic Breast Cancer, a Challenging Case Report of Bleeding Control and Palliative Wound Care
European Journal of Preventive Medicine
Volume 2, Issue 3, May 2014, Pages: 29-32
Received: May 7, 2014; Accepted: May 29, 2014; Published: Jun. 10, 2014
Views 3153      Downloads 312
Authors
Haynes Addison, Grandview Medical Center, Dayton Ohio, Clinical Instructor, CORE Group IV faculty, Ohio University Heritage College of Osteopathic Medicine
Simman Richard, Clinical Associate Professor in Plastic and Reconstructive Surgery, Associate Research Professor, Department of Pharmacology and Toxicology at Wright State University Boonshoft School of Medicine, Dayton, Ohio
Article Tools
Follow on us
Abstract
This case will discuss the palliative care in an advanced metastatic and fungating breast cancer. As sometimes happens, patients elect to go with different means of treatment and not the mastectomy with lymph node dissection, radiation, and chemotherapy that is the standard of care. Even though the patient elected not to attempt the full surgery, there are still surgical options that could have helped her quality of life and are important to consider. Wound care can be curative for many different wounds but can also greatly improve the quality of life that is present. Wounds leave the body exposed to secondary infections and can produce foul odor which is not conducive to patient or family comfort and happiness. It can be used in conjunction with many different treatments and should not be forgotten in the treatment of all patients. In this case we also discussed a variety of methods for bleeding control of this cancerous mass.
Keywords
Fungating Breast Cancer, Palliative Wound Care, Bleeding Control
To cite this article
Haynes Addison, Simman Richard, Fungating Metastatic Breast Cancer, a Challenging Case Report of Bleeding Control and Palliative Wound Care, European Journal of Preventive Medicine. Vol. 2, No. 3, 2014, pp. 29-32. doi: 10.11648/j.ejpm.20140203.11
References
[1]
Chia SK, Speers CH, D'yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O'reilly SE, Olivotto IA; The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2005, pp. 104(8):1742.
[2]
Cristofanilli M, Buzdar AU, Hortobágyi GN; Update on the management of inflammatory breast cancer. Oncologist. 2003, pp. 8(2):141.
[3]
Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P: Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005, pp. 104(8):1742.
[4]
Dafni U, Grimani I, Xyrafas A, Eleftheraki AG, Fountzilas G: Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat. 2010, pp. 119(3):621.
[5]
Li CI, Uribe DJ, Daling JR: Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005, pp. 93(9):1046.
[6]
Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M: International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011, pp. 22(3):515.
[7]
Kleer CG, van Golen KL, Merajver SD: Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res. 2000, pp. 2(6):423.
[8]
Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M: International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011, pp. 22(3):515.
[9]
Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS 3rd, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP, American Society of Clinical Oncology: American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005, pp. 23(30):7703.
[10]
Perez CA, Fields JN, Fracasso PM, Philpott G, Soares RL Jr, Taylor ME, Lockett MA, Rush C: Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer. 1994, pp. 74(1 Suppl):466
[11]
Yang, CH, Cristofanilli, M: Systemic treatments for inflammatory breast cancer. Breast Dis 2005-2006, pp. 22:55.
[12]
Thoms WW Jr, McNeese MD, Fletcher GH, Buzdar AU, Singletary SE, Oswald MJ: Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1989, pp. 17(4):739.
[13]
Harris EE, Schultz D, Bertsch H, Fox K, Glick J, Solin LJ: Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003, pp. 55(5):1200.
[14]
Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, Fornage B, Singletary SE, Sahin A, Buzdar AU, Valero V. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006, pp. 106(5):1000.
[15]
De Boer RH, Allum WH, Ebbs SR, Gui GP, Johnston SR, Sacks NP, Walsh G, Ashley S, Smith IE: Multimodality therapy in inflammatory breast cancer: is there a place for surgery? Ann Oncol. 2000, pp. 11(9):1147.
[16]
Brun B, Otmezguine Y, Feuilhade F, Julien M, Lebourgeois JP, Calitchi E, Roucayrol AM, Ganem G, Huart J, Pierquin B: Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation. Cancer. 1988, pp. 61(6):1096.
[17]
Bristol, IJ, Buchholz, TA: Inflammatory breast cancer: current concepts in local management. Breast Dis 2005- 2006, pp. 22:75.
[18]
Curcio LD, Rupp E, Williams WL, Chu DZ, Clarke K, Odom-Maryon T, Ellenhorn JD, Somlo G, Wagman LD: Beyond palliative mastectomy in inflammatory breast cancer--a reassessment of margin status. Ann Surg Oncol. 1999, pp. 6(3):249.
[19]
American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.
[20]
Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011, pp. 22:515.
[21]
Tai P, Yu E, Shiels R, et al. Short- and long-term cause-specific survival of patients with inflammatory breast cancer. BMC Cancer 2005, pp. 5:137.
[22]
Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005, pp. 97:966.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186